Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SKN015
MIFTS: 65

Skin Carcinoma

Categories: Cancer diseases, Rare diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Skin Carcinoma

About this section

MalaCards integrated aliases for Skin Carcinoma:

Name: Skin Carcinoma 12 56 15 17
Skin Cancer 12 54 56 44 3 15
Melanoma and Non-Melanoma Skin Cancer 12
Malignant Neoplasm of Skin 12
Carcinoma of Skin 12
Ca - Skin Cancer 12
Cancer of Skin 12
Cancer, Skin 41

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Skin diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3451 DOID:4159
MeSH 45 D012878
NCIt 51 C2920 C4914
SNOMED-CT 69 94047004
Sources

Summaries for Skin Carcinoma

About this section
MedlinePlus : 44 Skin cancer is the most common form of cancer in the United States. The two most common types are basal cell cancer and squamous cell cancer. They usually form on the head, face, neck, hands, and arms. Another type of skin cancer, melanoma, is more dangerous but less common. Anyone can get skin cancer, but it is more common in people who Spend a lot of time in the sun or have been sunburned Have light-colored skin, hair and eyes Have a family member with skin cancer Are over age 50 You should have your doctor check any suspicious skin markings and any changes in the way your skin looks. Treatment is more likely to work well when cancer is found early. If not treated, some types of skin cancer cells can spread to other tissues and organs. Treatments include surgery, radiation therapy, chemotherapy, photodynamic therapy (PDT), and biologic therapy. PDT uses a drug and a type of laser light to kill cancer cells. Biologic therapy boosts your body's own ability to fight cancer. NIH: National Cancer Institute

MalaCards based summary : Skin Carcinoma, also known as skin cancer, is related to squamous cell carcinoma and xeroderma pigmentosum, complementation group d. An important gene associated with Skin Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are G-Beta Gamma Signaling and Human cytomegalovirus infection. The drugs Aminolevulinic acid and Vindesine have been mentioned in the context of this disorder. Affiliated tissues include skin, kidney and t cells, and related phenotypes are Reduced mammosphere formation and growth/size/body region

Disease Ontology : 12 An integumentary system cancer located in the skin that is the uncontrolled growth of abnormal skin cells.

CDC : 3 Skin cancer is the most common form of cancer in the United States. The two most common types of skin cancer—basal cell and squamous cell carcinomas—are highly curable, but can be disfiguring and costly to treat. Melanoma, the third most common skin cancer, is more dangerous and causes the most deaths. The majority of these three types of skin cancer are caused by overexposure to ultraviolet (UV) light.

Sources

Related Diseases for Skin Carcinoma

About this section

Diseases in the Skin Carcinoma family:

Skin Carcinoma in Situ

Diseases related to Skin Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 409)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 32.2 CDH1 CTNNB1 IVL PTCH1 PTGS2 TP53
2 xeroderma pigmentosum, complementation group d 31.7 ERCC2 GSTM1 XPA
3 prostate cancer 31.3 CDH1 CDK4 CHGA CTNNB1 JUN KRT8
4 squamous cell carcinoma, head and neck 31.2 CDH1 CDK4 CTNNB1 GSTM1 MYC PTGS2
5 sweat gland cancer 30.9 KRT20 KRT8 TP53
6 basal cell carcinoma 30.6 CTNNB1 ERCC2 GLI1 GSTM1 IVL KRT20
7 xeroderma pigmentosum, variant type 30.2 ERCC2 PTCH1 TP53 XPA
8 small cell carcinoma 30.2 CHGA KRT20 TP53
9 adenoid squamous cell carcinoma 30.2 CDH1 KRT20 KRT8
10 papilloma 30.1 IVL KRT20 KRT8 TP53
11 mutagen sensitivity 30.1 ERCC2 GSTM1 TP53 XPA
12 adenoid cystic carcinoma 30.0 CDH1 CTNNB1 KRT20 TP53
13 lymphoepithelioma-like carcinoma 29.9 CDH1 KRT20 KRT8
14 merkel cell carcinoma 29.8 CHGA KRT20 KRT8 TP53
15 melanoma, cutaneous malignant 1 29.8 CDK4 CTNNB1 MC1R TP53
16 actinic keratosis 29.7 KRT20 MC1R PTGS2 TMC8 TP53
17 adenocarcinoma 29.6 CDH1 CDK4 CTNNB1 MYC PTGS2 TP53
18 ovarian cancer 29.2 CDH1 CDK4 CTNNB1 JUN MYC TP53
19 lung cancer susceptibility 3 29.2 CDH1 CDK4 CTNNB1 JUN KRT20 PTGS2
20 hepatocellular carcinoma 29.1 CDH1 CDK4 CTNNB1 GSTM1 JUN MYC
21 colorectal cancer 29.0 CDH1 CDK4 CTNNB1 GSTM1 JUN KRT20
22 lung cancer 28.8 CDH1 CDK4 CHGA ERCC2 GSTM1 JUN
23 palmoplantar hyperkeratosis with squamous cell carcinoma of skin and 46,xx sex reversal 12.4
24 skin carcinoma in situ 12.3
25 sarcomatoid squamous cell skin carcinoma 12.1
26 plantar verrucous skin carcinoma 12.1
27 skin cancer, non melanoma, childhood 12.0
28 basaloid squamous cell skin carcinoma 12.0
29 acantholytic squamous cell skin carcinoma 12.0
30 clear cell squamous cell skin carcinoma 12.0
31 pigmentation defects-palmoplantar keratoderma-skin carcinoma syndrome 12.0
32 skin squamous cell carcinoma 11.5
33 xeroderma pigmentosum, complementation group f 11.5
34 xeroderma pigmentosum, complementation group a 11.2
35 oculocutaneous albinism 11.2
36 acral lentiginous melanoma 11.2
37 epidermodysplasia verruciformis 1 11.2
38 skin pilomatrix carcinoma 11.2
39 basal cell nevus syndrome 11.1
40 cockayne syndrome b 11.1
41 lentigo maligna melanoma 11.1
42 metatypical basal cell carcinoma 11.0
43 cutaneous adenocystic carcinoma 11.0
44 malignant syringoma 11.0
45 malignant acrospiroma 11.0
46 eccrine papillary adenocarcinoma 11.0
47 pilomatrix carcinoma 11.0
48 xeroderma pigmentosum, complementation group c 11.0
49 anal margin carcinoma 11.0
50 cutaneous mucoepidermoid carcinoma 11.0

Graphical network of the top 20 diseases related to Skin Carcinoma:



Diseases related to Skin Carcinoma
Sources

Symptoms & Phenotypes for Skin Carcinoma

About this section

GenomeRNAi Phenotypes related to Skin Carcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CDH1 CDK4 CHGA GSTM1 JUN MYC

MGI Mouse Phenotypes related to Skin Carcinoma:

47 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.49 CDH1 CDK4 CHGA CTNNB1 ERCC2 GLI1
2 cellular MP:0005384 10.43 CDH1 CDK4 CTNNB1 ERCC2 GLI1 JUN
3 behavior/neurological MP:0005386 10.41 CDK4 CTNNB1 ERCC2 GLI1 JUN MC1R
4 endocrine/exocrine gland MP:0005379 10.4 CDH1 CDK4 CHGA CTNNB1 ERCC2 GLI1
5 homeostasis/metabolism MP:0005376 10.4 CDH1 CDK4 CHGA CTNNB1 ERCC2 JUN
6 cardiovascular system MP:0005385 10.36 CDH1 CDK4 CHGA CTNNB1 JUN KRT8
7 immune system MP:0005387 10.36 CDH1 CDK4 CTNNB1 ERCC2 JUN KRT8
8 embryo MP:0005380 10.34 CDH1 CDK4 CTNNB1 GLI1 JUN KRT8
9 mortality/aging MP:0010768 10.34 CDH1 CDK4 CHGA CTNNB1 ERCC2 GLI1
10 hematopoietic system MP:0005397 10.31 CDK4 CTNNB1 ERCC2 JUN KRT8 MC1R
11 integument MP:0010771 10.31 CDH1 CDK4 CTNNB1 ERCC2 JUN MC1R
12 digestive/alimentary MP:0005381 10.26 CDH1 CDK4 CTNNB1 GLI1 KRT8 MYC
13 neoplasm MP:0002006 10.23 CDH1 CDK4 CTNNB1 ERCC2 GLI1 MC1R
14 craniofacial MP:0005382 10.21 CTNNB1 GLI1 MC1R MYC PTCH1 TP53
15 nervous system MP:0003631 10.21 CDK4 CHGA CTNNB1 ERCC2 GLI1 JUN
16 no phenotypic analysis MP:0003012 10.14 CDH1 CHGA CTNNB1 GLI1 JUN MC1R
17 limbs/digits/tail MP:0005371 10.13 CTNNB1 GLI1 MC1R MYC PTCH1 TP53
18 hearing/vestibular/ear MP:0005377 10.12 CTNNB1 KRT8 MC1R MYC PTCH1 TP53
19 liver/biliary system MP:0005370 10.11 CDK4 CTNNB1 JUN KRT8 MYC PTGS2
20 muscle MP:0005369 10.08 CDK4 CHGA CTNNB1 MYC PTCH1 PTGS2
21 normal MP:0002873 10.07 CDH1 CDK4 CTNNB1 GLI1 JUN MYC
22 pigmentation MP:0001186 9.97 CDK4 CTNNB1 ERCC2 MC1R MYC PTCH1
23 reproductive system MP:0005389 9.97 CDH1 CDK4 CHGA CTNNB1 ERCC2 GLI1
24 renal/urinary system MP:0005367 9.86 CDK4 CHGA CTNNB1 GLI1 PTCH1 PTGS2
25 skeleton MP:0005390 9.61 CTNNB1 ERCC2 JUN MYC PTCH1 PTGS2
26 vision/eye MP:0005391 9.28 CDK4 CTNNB1 ERCC2 JUN PTCH1 PTGS2
Sources

Drugs & Therapeutics for Skin Carcinoma

About this section

Drugs for Skin Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 479)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 106-60-5 137
2
Vindesine Approved, Investigational Phase 4 53643-48-4, 59917-39-4 40839
3
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2 4342-03-4 5351166
4
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
5
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 46835353 5284616 6436030
6
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 6473866 445643 439492
7
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 70789204 6442177
8
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 22916-47-8 4189
9
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 185243-69-0
10
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
11
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 124-94-7 31307
12
Adalimumab Approved Phase 4,Phase 3,Phase 2 331731-18-1 16219006
13
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 99011-02-6 57469
14
Diclofenac Approved, Vet_approved Phase 4,Phase 2,Not Applicable 15307-86-5 3033
15
Bexarotene Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 153559-49-0 82146
16
Tofacitinib Approved, Investigational Phase 4,Phase 3,Phase 2 477600-75-2
17
Acetylcholine Approved, Investigational Phase 4,Phase 2 51-84-3 187
18
Bacitracin Approved, Vet_approved Phase 4,Phase 2 1405-87-4 10909430 439542
19
tannic acid Approved Phase 4,Phase 3,Not Applicable 1401-55-4
20 Ixekizumab Approved, Investigational Phase 4,Phase 3 1143503-69-8
21
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 1994-09-7, 94-09-7 2337
22
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 137-58-6 3676
23
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
24
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
25
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 110942-02-4, 85898-30-2
26
Vemurafenib Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 918504-65-1 23252090 42611257
27
Ipilimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 477202-00-9
28
Acitretin Approved Phase 4,Not Applicable 55079-83-9, 69427-46-9 6437841
29
Menthol Approved Phase 4 2216-51-5 16666
30
Atorvastatin Approved Phase 4 134523-00-5 60823
31
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 441411 12560
32
belimumab Approved Phase 4 356547-88-1 5957 10451420
33
Azathioprine Approved Phase 4 446-86-6 2265
34
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-70-2 271
35
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 1406-16-2
36
Calcitriol Approved, Nutraceutical Phase 4,Not Applicable 32222-06-3 5280453 134070
37 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Methyl 5-aminolevulinate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
42 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
43 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
45 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
48 Cyclosporins Phase 4,Phase 3,Phase 2
49 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 901)
# Name Status NCT ID Phase Drugs
1 Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate Unknown status NCT01491711 Phase 4 Methylaminolevulinate PDT in 2 sessions;Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
2 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4 Cisplatin, Vindesine, Dacarbazine (drugs)
3 Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients Completed NCT00129961 Phase 4 sirolimus;cyclosporine or tacrolimus
4 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
5 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Completed NCT00847912 Phase 4 5-fluorouracil;Placebo, vehicle control
6 Individually Adapted Immunosuppression in de Novo Renal Transplantation Based on Immune Function Monitoring: a Prospective Randomised Study Completed NCT00895206 Phase 4 individual adapted immunosuppression;golden standard therapy
7 Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome Completed NCT00266656 Phase 4 Humatrope
8 An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation Completed NCT01644396 Phase 4
9 Photosensitivity of the Skin Under Azathioprin in Renal Transplant Recipients Completed NCT00492895 Phase 4 Discontinuation of Azathioprin
10 Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell Carcinoma Completed NCT00204555 Phase 4 Imiquimod
11 Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients Completed NCT02866695 Phase 4 ingenol mebutate gel 0.015%
12 UVB Light and Sunscreen Completed NCT00818467 Phase 4
13 Comparison of the Efficacy and Tolerability of Solaraze for 3 Versus 6 Months in Patients With Mild to Moderate Actinic Keratosis Located on the Face and Head Completed NCT00204542 Phase 4 Diclofenac;Diclofenac
14 Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL) Completed NCT01007448 Phase 4 bexarotene;bexarotene
15 Safety and Efficacy of Combining nbUVB to Etanercept in Patients Completed NCT00640393 Phase 4 Etanercept
16 Community Based Trial for AMEVIVE® Completed NCT00168753 Phase 4 Alefacept
17 PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis Completed NCT01766440 Phase 4 Calcitriol 3 mcg/g ointment
18 Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis Recruiting NCT02092467 Phase 4 tofacitinib;tofacitinib
19 Menthol for PDT Pain Relief Recruiting NCT02984072 Phase 4 Menthol;Aqueous Cream
20 A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis Recruiting NCT03915964 Phase 4 Baricitinib;TNF Inhibitor
21 A Clinical Trial of STAtin Therapy for Reducing Events in the Elderly (STAREE) Recruiting NCT02099123 Phase 4 Atorvastatin;Placebo (for Atorvastatin)
22 Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer Recruiting NCT01459666 Phase 4 Dysport (abobotulinumtoxinA);Bacteriostatic 0.9% Sodium Chloride (vehicle)
23 Topical Antibiotic Prophylaxis for Eyelids Recruiting NCT03199911 Phase 4 Topical Anti-Infective Product;Topical Ointment
24 A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis Recruiting NCT03573323 Phase 4 Ixekizumab;Guselkumab;Placebo
25 Efficacy of Rapamycin (Sirolimus) in the Treatment of BRBNS, Hereditary or Sporadic Venous Malformation Recruiting NCT03767660 Phase 4 Rapamycin
26 Pain Outcomes Following Intralesional Corticosteroid Injections Recruiting NCT03630198 Phase 4 Corticosteroid with lidocaine;Corticosteroid with normal saline
27 Belimumab Assessment of Safety in SLE Active, not recruiting NCT01705977 Phase 4
28 ASCEND: A Study of Cardiovascular Events iN Diabetes Active, not recruiting NCT00135226 Phase 4 Aspirin;Omega-3 Ethyl Esters;Placebo Aspirin;Placebo Omega-3 Ethyl Esters
29 Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5% Active, not recruiting NCT01926496 Phase 4 Ingenol Mebutate Gel, 0.015%;Imiquimod Cream, 5%
30 Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis Active, not recruiting NCT02125279 Phase 4 Calcitriol
31 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT00866684 Phase 4 Sirolimus;Azathioprine;Mycophenolate;Ciclosporin;Tacrolimus
32 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4 Sirolimus
33 HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4 vemurafenib + HD IL-2
34 HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4 High Dose Interleukin-2;Ipilimumab
35 Acitretin Plasma Levels Under Hemodialysis Withdrawn NCT00488384 Phase 4 Chemopreventive application (Acitretin)
36 CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial Unknown status NCT00799188 Phase 3 Everolimus
37 T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma Pigmentosum Unknown status NCT00002811 Phase 3 liposomal T4N5 lotion
38 Virus Early Transcription Factor (VETF) Multicenter Phototherapy Protocol Unknown status NCT00525395 Phase 3
39 Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients Unknown status NCT01729663 Phase 2, Phase 3 interferon alpha 2b
40 Preoperative Acetaminophen and Carbohydrate Loading Completed NCT03131713 Phase 3 Acetaminophen
41 PDT With Metvix® 160 mg/g Cream in Organ Transplant Recipients With Non-melanoma Skin Cancer Completed NCT00472459 Phase 3
42 Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer Completed NCT00007631 Phase 3 Tretinoin 0.1% cream or placebo
43 Comparison of Two Schemes of Cryosurgery and Imiquimod Combination Treatment for Basal Cell Carcinoma Completed NCT01212549 Phase 3
44 Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer Completed NCT00005884 Phase 3 eflornithine
45 Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer Completed NCT00066872 Phase 3 imiquimod
46 Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals. Completed NCT00272428 Phase 3
47 Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer Completed NCT00021255 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel;Herceptin;Carboplatin
48 Study of Etanercept in the Treatment of Psoriasis in Adult Subjects Completed NCT00121615 Phase 3 etanercept
49 Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer Completed NCT00000479 Phase 3 Aspirin;Vitamin E
50 Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery Completed NCT00326898 Phase 3 Sorafenib;Sunitinib

Search NIH Clinical Center for Skin Carcinoma

Sources

Genetic Tests for Skin Carcinoma

About this section
Sources

Anatomical Context for Skin Carcinoma

About this section

MalaCards organs/tissues related to Skin Carcinoma:

42
Skin, Kidney, T Cells, Testes, Liver, Lymph Node, Brain

The Foundational Model of Anatomy Ontology organs/tissues related to Skin Carcinoma:

20
The Skin
Sources

Publications for Skin Carcinoma

About this section

Articles related to Skin Carcinoma:

(show top 50) (show all 3387)
# Title Authors Year
1
Lack of association of metastasis-associated lung adenocarcinoma transcript 1 variants with melanoma skin cancer risk. ( 30870271 )
2019
2
Appropriate use criteria for basal cell carcinoma Mohs surgery at a single center in the face of high-burden skin cancer: a retrospective cohort study. ( 29727201 )
2019
3
Behavior Issues, Skin Cancer, Adolescent Depression, Prostate Cancer, Deprescribing Antipsychotics. ( 30702247 )
2019
4
Reduced-Intensity Conditioning Regimens, Prior Chronic Lymphocytic Leukemia, and Graft-Versus-Host Disease Are Associated with Higher Rates of Skin Cancer after Allogeneic Hematopoietic Stem Cell Transplantation. ( 30316899 )
2019
5
Association of Hypothyroidism With Nonmelanoma Skin Cancer in the Multiethnic Cohort Population-Based Study. ( 30260811 )
2019
6
Immunobiochemical Reconstruction of Influenza Lung Infection-Melanoma Skin Cancer Interactions. ( 30745900 )
2019
7
The influence of immunosuppressants on the non-melanoma skin cancer among patients with systemic lupus erythematosus and primary Sjögren's syndrome: a nationwide retrospective case-control study in Taiwan. ( 31074727 )
2019
8
Pathological review of primary cutaneous malignant melanoma by a specialist skin cancer multidisciplinary team improves patient care in the UK. ( 31088937 )
2019
9
Comparison of quality of life between melanoma and non-melanoma skin cancer patients. ( 31106760 )
2019
10
Early Detection of Skin Cancer Using Melanoma Segmentation technique. ( 31111236 )
2019
11
High melanoma risk in non-melanoma skin cancer patients under age 40: a large retrospective cohort study. ( 31042854 )
2019
12
Estimating the health care costs of non-melanoma skin cancer in Saskatchewan using physician billing data. ( 31043813 )
2019
13
MHRA drug safety update: hydrochlorothiazide and non-melanoma skin cancer. ( 31018928 )
2019
14
Incidence of complications in dermatological surgery of melanoma and non-melanoma skin cancer in patients with multiple comorbidity and/or antiplatelet-anticoagulants. Five year experience in our Hospital. ( 30951034 )
2019
15
Evaluation of Pre-Operative Quality of Life in Non-Melanoma Skin Cancer Patients. ( 30954579 )
2019
16
Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Non-Melanoma Skin Cancer. ( 30963614 )
2019
17
Mucosal human papillomavirus detection and TP53 immunohistochemical expression in non-melanoma skin cancer in Tunisian patients. ( 30972814 )
2019
18
Superficial radiotherapy for non-melanoma skin cancer of the lip: a 44-year Italian experience. ( 30973789 )
2019
19
Non-Melanoma Skin Cancer Tumor's Characteristics and Histologic Subtype as a Predictor for Subclinical Spread and Number of Mohs Stages required to Achieve Tumor-Free Margins. ( 30924914 )
2019
20
The signaling effects of ATP on melanoma-like skin cancer. ( 30926387 )
2019
21
The role of radiotherapy in the management of non-melanoma skin cancer. ( 30931531 )
2019
22
Immunotherapy in non-melanoma skin cancer: updates and new perspectives. ( 30936937 )
2019
23
Long-term experience with radiotherapy for the treatment of non-melanoma skin cancer. ( 30892970 )
2019
24
Skin cancer in organ transplant recipients: Dynamics in the incidence and clinical predictors for the first and subsequent posttransplant non-melanoma-skin cancer. ( 30811675 )
2019
25
Peri-operative delineation of non-melanoma skin cancer margins in vivo with handheld reflectance confocal microscopy and video-mosaicking. ( 30811707 )
2019
26
Investigation of three oncogenic epitheliotropic viruses shows human papillomavirus in association with non-melanoma skin cancer. ( 30788731 )
2019
27
WHO/ILO work-related burden of disease and injury: Protocol for systematic reviews of occupational exposure to solar ultraviolet radiation and of the effect of occupational exposure to solar ultraviolet radiation on melanoma and non-melanoma skin cancer. ( 30792021 )
2019
28
Mobile Teledermatology for Melanoma Detection. Assessment of Validity in the Framework of a Population-based Skin Cancer Awareness Campaign in Northern Italy. ( 30797846 )
2019
29
Coffee, tea, caffeine, and risk of non-melanoma skin cancer in a Chinese population: The Singapore Chinese Health Study. ( 30731173 )
2019
30
Long-term follow-up in patients treated with electrochemotherapy for non-melanoma skin cancer in the head and neck area. ( 30734631 )
2019
31
Occupational differences in standardized mortality ratios for non-melanotic skin cancer and melanoma in exposed areas among individuals with Fitzpatrick skin types III and IV. ( 30761684 )
2019
32
Satellite and In-Transit Metastatic Disease in Melanoma Skin Cancer: A Retrospective Review of Disease Presentation, Treatment, and Outcomes. ( 30681423 )
2019
33
FRAIL scale as a predictor of complications and mortality in older patients undergoing reconstructive surgery for non-melanoma skin cancer. ( 30655763 )
2019
34
Trends in the treatment and prevention of keratinocyte carcinoma (non-melanoma skin cancer). ( 30660857 )
2019
35
Vitamin D enzymes (CYP27A1, CYP27B1, and CYP24A1) and receptor expression in non-melanoma skin cancer. ( 30668811 )
2019
36
Optical coherence tomography imaging of melanoma skin cancer. ( 30539405 )
2019
37
Public Health Implications of Google Searches for Sunscreen, Sunburn, Skin Cancer, and Melanoma in the United States. ( 30428681 )
2019
38
Morphea and systemic sclerosis are associated with an increased risk for melanoma and nonmelanoma skin cancer. ( 30352282 )
2019
39
Harnessing the gatekeepers of glucocorticoids for chemoprevention of non-melanoma skin cancer. ( 30302860 )
2019
40
An international comparison of Google searches for sunscreen, sunburn, skin cancer, and melanoma: Current trends and public health implications. ( 30198586 )
2019
41
Polygenic risk score as a determinant of risk of non-melanoma skin cancer in a European-descent renal transplant cohort. ( 30085400 )
2019
42
The role of sunscreen in the prevention of cutaneous melanoma and nonmelanoma skin cancer. ( 30012373 )
2019
43
PDGFR-induced autocrine SDF-1 signaling in cancer cells promotes metastasis in advanced skin carcinoma. ( 30874597 )
2019
44
Integrating the concept of field cancerization in the classification and risk assessment of cutaneous squamous cell carcinoma: proposal for a new classification and terminology of keratinocyte skin cancer. ( 30980765 )
2019
45
Skin cancer precursor immunotherapy for squamous cell carcinoma prevention. ( 30895944 )
2019
46
Hydrochlorothiazide and the risk of skin cancer. A scientific statement of the British and Irish Hypertension Society. ( 30842544 )
2019
47
The 308-nm excimer laser treatment does not increase the risk of skin cancer in patients with vitiligo: A population-based retrospective cohort study. ( 30849210 )
2019
48
Erectile Dysfunction Medications and Skin Cancer: An Analysis in US Veterans. ( 30735744 )
2019
49
Skin Cancer Knowledge and Photoprotective Practices of Organ Transplant Recipients. ( 30860618 )
2019
50
'Try to make good hay in the shade - it won't work!' A qualitative interview study on the perspectives of Bavarian farmers regarding primary prevention of skin cancer. ( 30861096 )
2019
Sources

Variations for Skin Carcinoma

About this section
Sources

Expression for Skin Carcinoma

About this section
Search GEO for disease gene expression data for Skin Carcinoma.
Sources

Pathways for Skin Carcinoma

About this section

Pathways related to Skin Carcinoma according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
G-Beta Gamma Signaling 65
Show member pathways
 12.98 CTNNB1 GLI1 IVL JUN PTCH1 PTGS2
2
Human cytomegalovirus infection 38
Show member pathways
 12.92 CDK4 CTNNB1 JUN MYC PTGS2 TP53
3
Endometrial cancer 38
Show member pathways
 12.81 CDH1 CDK4 CTNNB1 JUN MYC TP53
4
Development HGF signaling pathway 23
Show member pathways
 12.67 CDH1 CTNNB1 JUN PTGS2 TP53
5
Chks in Checkpoint Regulation 65
Show member pathways
 12.66 CDK4 ERCC2 MYC TP53 XPA
6
Gastric cancer 38
Show member pathways
 12.58 CDH1 CDK4 CTNNB1 GSTM1 JUN MYC
7
Development EGFR signaling pathway 23
Show member pathways
 12.49 CDH1 CTNNB1 JUN MYC TP53
8
Wnt Signaling Pathways: beta-Catenin-dependent Wnt Signaling 66
Show member pathways
 12.4 CTNNB1 GLI1 PTCH1 TP53
9
Cell cycle 38 1
12.33 CDH1 CDK4 MYC TP53
10
Human T-cell leukemia virus 1 infection 38
12.27 CDK4 CTNNB1 JUN MYC TP53
11
Proteoglycans in cancer 38
12.25 CTNNB1 MYC PTCH1 TP53
12
Colorectal Cancer Metastasis 65
12.05 CDH1 CTNNB1 MYC PTGS2 TP53
13
Pathways in cancer 38
12.05 CDH1 CDK4 CTNNB1 GLI1 GSTM1 JUN
14
Fluid shear stress and atherosclerosis 38
12.04 CTNNB1 GSTM1 JUN TP53
15
Spinal Cord Injury 1
11.96 CDK4 MYC PTGS2 TP53
16
SMAD Signaling Network 65
11.96 CTNNB1 ERCC2 JUN TP53 XPA
17
DNA Damage Response (only ATM dependent) 1
11.93 CTNNB1 JUN MYC TP53
18
WNT Signaling 65
11.9 CDH1 CDK4 CTNNB1 JUN MYC PTGS2
19
Glioblastoma Multiforme 65
11.89 CDK4 CTNNB1 MYC TP53
20
Integrated Breast Cancer Pathway 1
11.82 CDH1 CDK4 CTNNB1 JUN MYC TP53
21
Retinoblastoma (RB) in Cancer 1
11.8 CDK4 MYC TP53
22
Small cell lung cancer 38
11.79 CDK4 MYC PTGS2 TP53
23
Validated targets of C-MYC transcriptional activation 1
11.76 CDK4 MYC TP53
24
C-MYB transcription factor network 1
11.74 GSTM1 MYC PTGS2
25
Regulation of nuclear SMAD2/3 signaling 1
11.74 CDK4 JUN MYC
26
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.73 CDK4 JUN PTGS2
27
Cell cycle Cell cycle (generic schema) 23
Show member pathways
 11.73 CDH1 CDK4 CTNNB1 JUN MYC PTGS2
28
Regulation of Wnt-mediated beta catenin signaling and target gene transcription 1
11.71 CDH1 CTNNB1 JUN MYC
29
Platinum drug resistance 38
11.7 GSTM1 TP53 XPA
30
Association Between Physico-Chemical Features and Toxicity Associated Pathways 1
11.67 CTNNB1 JUN MYC
31
Human Thyroid Stimulating Hormone (TSH) signaling pathway 1
11.66 CDK4 JUN MYC
32
Bladder cancer 1 38
11.66 CDH1 CDK4 MYC TP53
33
Transcription_P53 signaling pathway 23
11.59 CTNNB1 ERCC2 JUN TP53 XPA
34
Integrated Cancer Pathway 1
11.47 CDK4 MYC TP53
35
Presenilin action in Notch and Wnt signaling 1
11.46 CTNNB1 JUN MYC
36
DNA damage_ATM/ATR regulation of G1/S checkpoint 23
11.44 CDK4 MYC TP53
37
Hepatitis C and Hepatocellular Carcinoma 1
11.41 JUN MYC PTGS2 TP53
38
Gastric Cancer Network 2 1
11.28 CTNNB1 MYC TP53
39
Platinum Pathway, Pharmacokinetics/Pharmacodynamics 62
11.2 ERCC2 GSTM1 XPA
40
Signaling mediated by p38-alpha and p38-beta 1
11.17 JUN KRT8 PTGS2 TP53
41
RHO GTPases activate IQGAPs 67
10.8 CDH1 CTNNB1
Sources

GO Terms for Skin Carcinoma

About this section

Cellular components related to Skin Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.53 CDH1 CDK4 CTNNB1 ERCC2 GLI1 GSTM1
2 perinuclear region of cytoplasm GO:0048471 9.43 CDH1 CDK4 CHGA CTNNB1 PTCH1 TYR
3 flotillin complex GO:0016600 9.16 CDH1 CTNNB1

Biological processes related to Skin Carcinoma according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.95 CTNNB1 ERCC2 MYC TP53 TYR
2 in utero embryonic development GO:0001701 9.92 CTNNB1 ERCC2 MYC PTCH1
3 positive regulation of apoptotic process GO:0043065 9.89 CDK4 CTNNB1 JUN PTGS2 TP53
4 positive regulation of cell proliferation GO:0008284 9.88 CDK4 CTNNB1 GLI1 JUN MYC PTGS2
5 regulation of cell proliferation GO:0042127 9.86 CDK4 CTNNB1 PTCH1 PTGS2
6 positive regulation of smooth muscle cell proliferation GO:0048661 9.77 JUN MYC PTGS2
7 positive regulation of fibroblast proliferation GO:0048146 9.74 CDK4 JUN MYC
8 cellular response to UV GO:0034644 9.71 MYC PTGS2 TP53
9 response to UV GO:0009411 9.7 ERCC2 TYR XPA
10 cellular process GO:0009987 9.66 CTNNB1 JUN
11 regulation of osteoblast differentiation GO:0045667 9.65 CTNNB1 GLI1
12 melanin biosynthetic process GO:0042438 9.65 MC1R TYR
13 ovulation GO:0030728 9.65 MYC PTGS2
14 nucleotide-excision repair GO:0006289 9.65 ERCC2 TP53 XPA
15 UV-damage excision repair GO:0070914 9.64 MC1R XPA
16 negative regulation of blood vessel diameter GO:0097756 9.64 CHGA PTGS2
17 entry of bacterium into host cell GO:0035635 9.63 CDH1 CTNNB1
18 branching involved in ureteric bud morphogenesis GO:0001658 9.63 CTNNB1 MYC PTCH1
19 negative regulation of cell division GO:0051782 9.62 MYC PTCH1
20 response to estradiol GO:0032355 9.62 CTNNB1 MYC PTCH1 PTGS2
21 positive regulation of DNA-templated transcription, initiation GO:2000144 9.61 CTNNB1 JUN
22 dorsal/ventral pattern formation GO:0009953 9.61 CTNNB1 GLI1 PTCH1
23 cellular response to phorbol 13-acetate 12-myristate GO:1904628 9.59 CDK4 MYC
24 hair cell differentiation GO:0035315 9.58 CTNNB1 ERCC2
25 hair cycle process GO:0022405 9.58 CTNNB1 ERCC2
26 response to organic substance GO:0010033 9.56 CDH1 CDK4 JUN PTGS2
27 positive regulation of transcription, DNA-templated GO:0045893 9.56 CDH1 CTNNB1 ERCC2 GLI1 JUN MYC
28 liver regeneration GO:0097421 9.54 GLI1 MYC PTCH1
29 cellular response to indole-3-methanol GO:0071681 9.51 CDH1 CTNNB1
30 UV protection GO:0009650 9.33 ERCC2 MC1R XPA
31 response to drug GO:0042493 9.17 CDH1 CDK4 CTNNB1 JUN MYC PTCH1
32 positive regulation of transcription by RNA polymerase II GO:0045944 10.16 CTNNB1 ERCC2 GLI1 JUN MC1R MYC
33 negative regulation of cell proliferation GO:0008285 10.03 CTNNB1 JUN PTCH1 PTGS2 TP53

Molecular functions related to Skin Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.72 CTNNB1 JUN MYC TP53 TYR
2 protein homodimerization activity GO:0042803 9.63 CDH1 GSTM1 JUN PTGS2 TYR XPA
3 protein binding GO:0005515 9.58 CDH1 CDK4 CTNNB1 ERCC2 GLI1 IVL
4 enzyme binding GO:0019899 9.35 CTNNB1 GSTM1 JUN PTGS2 TP53
5 mechanosensitive ion channel activity GO:0008381 9.26 TMC6 TMC8
Sources

Sources for Skin Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....